By proceeding, you agree to our Terms of Use and Privacy Policy.
jCyte is a clinical-stage company focused on the application of progenitor cell-based technology in retinal diseases. The Company's allogeneic product candidate, jCell, is delivered by simple intravitreal injection without the need for surgery or immune suppression. jCyte has completed a phase 1/2a, phase 1/2a extension and phase 2b clinical trials testing jCell in patients with Retinitis Pigmentosa.
27-27 July 2023
Welcome to OIS Retina 2023, the leading gathering of clinical, corporate, and capital leaders dedicated to advancing novel technologies and addressing the most significant unmet medical needs in the field of retina. This highly anticipated event brin
Event Ended
USA
Paid
Seattle